|
KMID : 0923620140140030156
|
|
Immune Network
2014 Volume.14 No. 3 p.156 ~ p.163
|
|
|
Reduced Interleukin-17 and Transforming Growth Factor Beta Levels in Peripheral Blood as Indicators for Following the Course of Bladder Cancer
|
|
Baharlou Rasoul
Vasmehjani Abbas Ahmadi
Dehghani Ali
Ghobadifar Mohamed Amin
Khoubyari Mahshid
|
|
|
Abstract
|
|
|
|
Interleukin (IL) 17 is produced by T-helper (Th) 17 with a vig-orous effect on cells of the immune system playing important roles in pathogenesis of immune-mediated diseases, includ-ing autoimmune disorders and cancers. Therefore, the aim of current study was to determine the serum levels of IL-6, IL-17, and transforming growth factor beta (TGF-β) in Iranian bladder cancer patients, and to correlate them with disease status. Blood samples were collected from 40 blad-der cancer patients and 38 healthy individuals with no history of malignancies or autoimmune disorders. The serum levels of IL-6, IL-17, and TGF-β were measured by the en-zyme-linked immunosorbent assay (ELISA). The results showed that the levels of IL-17 (p＜0.0001) and TGF-β (p＜0.0001) were significantly lower in the patients com-pared to the controls. No significant differences in the level of serum IL-6 (p=0.16) was observed between the patients and controls. In addition, demographic characteristics be-tween control and patients groups were not significantly different. As most of the cases studied in this investigation were in stage I and II, it is concluded that reduced Th17-re-lated cytokines can be used as indicators for following the course and clinical stages of bladder carcinoma progress and immune response to cancer.
|
|
|
KEYWORD
|
|
|
Bladder cancer, Interleukin-6, Interleukin-17, Transforming growth factor beta
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
   
|